Fundraising FoxNovartis
also invests · investor profileUnicorn exit · $1.7Bacquired by MorphoSysBasel, CH · 5 known investors
Find your way into Novartis
Sign up to see every warm intro you have to Novartis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Novartis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by MorphoSys AG June 2021 · $1.7B ($34.00 per share in cash, total equity value of $1.7 billion) · source ↗
Novartis is a pharmaceutical company that develops and markets prescription medicines for patients across therapeutic areas including multiple sclerosis, breast cancer, and inflammatory conditions. Its medicines include treatments for HR+/HER2- early breast cancer and polymyalgia rheumatica.
Investors · 5
Founder mafia
18 people who came through Novartis went on to found or lead other companies.
+ 6 more
Acquisitions · 6
Early investors' stakes continue via these dealsNovartis is a pharmaceutical company developing breakthrough medicines across therapeutic areas including oncology and cardiovascular disease.
Developing best-in-class protein therapeutics for rapidly relieving or preventing allergic-mediated diseases.
Mariana Oncology was a Cambridge/Watertown, MA clinical-stage biotech developing targeted radiopharmaceutical conjugates delivering alpha- and beta-emitting radionuclides to treat cancers, including lead candidate MC-339 for small cell lung cancer.
Regulus Therapeutics was a San Diego-based clinical-stage biopharmaceutical company developing oligonucleotide drugs that inhibit disease-causing microRNAs. Its lead program, farabursen, targeted miR-17 for treating autosomal dominant polycystic kidney disease.
Spinifex Pharmaceuticals was a US-Australian clinical-stage biotech developing treatments for chronic pain. Its lead candidate, EMA401, was an oral AT2 receptor antagonist targeting neuropathic pain without CNS side effects.
The Medicines Company was a New Jersey-based biopharmaceutical company developing cardiovascular drugs, notably inclisiran, an RNA-interference therapy for lowering LDL cholesterol.
Frequently asked questions
- What does Novartis do?
- Novartis is a pharmaceutical company that develops and markets prescription medicines for patients across therapeutic areas including multiple sclerosis, breast cancer, and inflammatory conditions. Its medicines include treatments for HR+/HER2- early breast cancer and polymyalgia rheumatica.
- Who are Novartis's investors?
- Novartis's investors include Clal Biotechnology Industries, ExSight Ventures, Longitude Capital, Tachyon Ventures, The Column Group.
- Who acquired Novartis?
- Novartis was acquired by MorphoSys.
- Where is Novartis headquartered?
- Novartis is headquartered in Basel, CH.